Earnings Summary

Abbott Laboratories’s revenue fell -11.36% since last year same period to $9978Mn in the Q2 2023. On a quarterly growth basis, Abbott Laboratories has generated 2.37% jump in its revenue since last 3-months.

Abbott Laboratories’s net profit fell -31.86% since last year same period to $1375Mn in the Q2 2023. On a quarterly growth basis, Abbott Laboratories has generated 4.32% jump in its net profits since last 3-months.

Abbott Laboratories’s net profit margin fell -23.13% since last year same period to 13.78% in the Q2 2023. On a quarterly growth basis, Abbott Laboratories has generated 1.91% jump in its net profit margins since last 3-months.

Abbott Laboratories’s earning per share (EPS) estimates for the current quarter stand at 0.91 - a -3.19% fall from last quarter’s estimates.

Abbott Laboratories’s earning per share (EPS) estimates for the current year stand at 0.91.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Abbott Laboratories’s return on assets (ROA) stands at 0.06.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Abbott Laboratories’s return on equity (ROE) stands at 0.14.

Abbott Laboratories declared 0.51 dividend per share during the earnings announcement for Q1 2023.